Castle Biosciences CSTL Accumulated Depreciation
Accumulated Depreciation at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization.
The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Castle Biosciences's accumulated depreciation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Castle Biosciences's accumulated depreciation?
- Castle Biosciences (CSTL) reported accumulated depreciation of $19.86M in Q1 2026.
- How has Castle Biosciences's accumulated depreciation changed year-over-year?
- Castle Biosciences's accumulated depreciation increased by 39.7% year-over-year, from $14.22M to $19.86M.
- What is the long-term trend for Castle Biosciences's accumulated depreciation?
- Over 5 years (2020 to 2025), Castle Biosciences's accumulated depreciation has grown at a 61.7% compound annual growth rate (CAGR), from $1.65M to $18.3M.
- What does accumulated depreciation mean?
- Total accumulated depreciation on property, plant, and equipment since acquisition — represents the consumed portion of asset useful lives.